Clinical trial
Growth and Development, Health-related Quality of Life of Children With Transfusion-dependent Beta-thalassemia After Gene Therapy
Name
GDH-001
Description
The investigate will conduct a cohort study to compare the growth and development, metabolism, lifestyle behavior, and health-related quality of life among three groups: children with transfusion-dependent β-thalassemia (TDT) who have received gene therapy, TDT children with lifelong supportive therapy and healthy children.
Trial arms
Trial start
2023-06-05
Estimated PCD
2028-12-31
Trial end
2029-12-31
Status
Recruiting
Treatment
Gene therapy
Autologous edited hematopoietic stem cell transplantation
Arms:
Gene therapy group
Size
100
Primary endpoint
Growth in pediatric subjects will be assessed by height.
Up to 5 years.
Growth in pediatric subjects will be assessed by weight.
Up to 5 years.
Growth in pediatric subjects will be assessed by the head and chest circumference.
Up to 5 years.
Growth in pediatric subjects will be assessed by interocular distance.
Up to 5 years.
Growth in pediatric subjects will be assessed by bone density.
Up to 5 years.
The pubertal status will be measured using by Tanner scale.
Up to 5 years.
Hormonal levels will be measured by clinical examination.
Up to 5 years.
Quality of life will be measured using by Pediatric Quality of Life Inventory (PedsQL) at baseline and the end of the study.
Up to 5 years.
Lifestyle behaviors will be assessed by general questioning.
Up to 5 years.
Eligibility criteria
Inclusion Criteria:
Gene therapy group-inclusion
* Male or female age of 3-14 years
* TDT Children who have received gene therapy.
* Subjects who are willing and able to provide written informed consent.
Supportive therapy group-inclusion
* Gender same as the matched case
* Age similar to the matched case
* Children with β-TDT
* No history of gene therapy or allogeneic hematopoietic stem cell transplantation
* Subjects who are willing and able to provide written informed consent.
Healthy children group-inclusion
* Gender same as the matched case
* Age similar to the matched case
* Subjects who are willing and able to provide written informed consent.
Exclusion Criteria:
* Diagnosis of compound α-thalassemia
* Uncontrolled systemic fungal, bacterial, or viral infection
* History of malignant solid tumors, myeloproliferative or immunodeficiency diseases
* Diagnosed with mental illness
* Patients considered to be ineligible for the study by the investigator for reasons other than the above
Discontinuation of Study :
* Subjects who are unwilling or unable to continue participating in the study (withdrawal of informed consent) may withdraw from the study
* Subjects who received gene therapy or allogeneic hematopoietic stem cell transplantation during the study
* The subject is seriously non-compliant with the study requirements, such as missing 2 consecutive visits
* Subject lost to follow-up
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'The peripheral blood sample was collected and stored in the IHBDH biobank.'}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}
Updated at
2023-08-14
1 organization
1 product
2 indications
Product
Gene therapyIndication
Beta-ThalassemiaIndication
Gene Therapy